Dry Eye Disease Therapeutics
1. Miebo patent expiration
Treatment: Treatment of the signs and symptoms of dry eye disease (ded)
MIEBO IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10576154 | BAUSCH AND LOMB INC | Semifluorinated alkane compositions |
Sep, 2033
(7 years from now) | |
| US10507132 | BAUSCH AND LOMB INC | Topical administration method |
Jun, 2037
(11 years from now) | |
| US10449164 | BAUSCH AND LOMB INC | Methods of treating ocular disorders using semifluorinated alkanes |
Sep, 2033
(7 years from now) | |
| US10369117 | BAUSCH AND LOMB INC | Compositions comprising mixtures of semifluorinated alkanes |
Sep, 2033
(7 years from now) | |
| US10058615 | BAUSCH AND LOMB INC | Semifluorinated alkane compositions |
Sep, 2033
(7 years from now) | |
| US11357738 | BAUSCH AND LOMB INC | Semifluorinated compounds and their compositions |
Sep, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 18, 2028 |
Drugs and Companies using PERFLUOROHEXYLOCTANE ingredient
NCE-1 date: 19 May, 2027
Market Authorisation Date: 18 May, 2023
Dosage: SOLUTION/DROPS
More Information on Dosage
MIEBO family patents
2. Xiidra patent expiration
Treatment: Treatment of signs and symptoms of dry eye disease (ded); Treatment of the signs and symptoms of Read More
Can you believe XIIDRA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7928122 | BAUSCH AND LOMB INC | Modulators of cellular adhesion |
Nov, 2024
(1 year, 2 months ago) | |
| US7745460 | BAUSCH AND LOMB INC | Modulators of cellular adhesion |
Nov, 2024
(1 year, 2 months ago) | |
| US9890141 | BAUSCH AND LOMB INC | Crystalline pharmaceutical and methods of preparation and use thereof |
Oct, 2030
(4 years from now) | |
| US7314938 | BAUSCH AND LOMB INC | Modulators of cellular adhesion |
Mar, 2025
(9 months ago) | |
| US8084047 | BAUSCH AND LOMB INC | Compositions and methods for treatment of eye disorders |
May, 2026
(4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8592450 | BAUSCH AND LOMB INC | Compositions and methods for treatment of eye disorders |
May, 2026
(4 months from now) | |
| US8367701 | BAUSCH AND LOMB INC | Crystalline pharmaceutical and methods of preparation and use thereof |
Apr, 2029
(3 years from now) | |
| US9216174 | BAUSCH AND LOMB INC | Modulators of cellular adhesion |
Nov, 2024
(1 year, 2 months ago) | |
| US8168655 | BAUSCH AND LOMB INC | Compositions and methods for treatment of eye disorders |
May, 2029
(3 years from now) | |
| US7790743 | BAUSCH AND LOMB INC | Modulators of cellular adhesion |
Nov, 2024
(1 year, 2 months ago) | |
| US10124000 | BAUSCH AND LOMB INC | Modulators of cellular adhesion |
Nov, 2024
(1 year, 2 months ago) | |
| US9447077 | BAUSCH AND LOMB INC | Crystalline pharmaceutical and methods of preparation and use thereof |
Apr, 2029
(3 years from now) | |
| US8927574 | BAUSCH AND LOMB INC | Crystalline pharmaceutical and methods of preparation and use thereof |
Nov, 2030
(4 years from now) | |
| US9085553 | BAUSCH AND LOMB INC | LFA-1 inhibitor and methods of preparation and polymorph thereof |
Jul, 2033
(7 years from now) | |
| US11058677 | BAUSCH AND LOMB INC | LFA-1 inhibitor formulations |
Dec, 2033
(7 years from now) | |
| US9353088 | BAUSCH AND LOMB INC | Crystalline pharmaceutical and methods of preparation and use thereof |
Oct, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 11, 2021 |
Drugs and Companies using LIFITEGRAST ingredient
NCE-1 date: 11 July, 2020
Market Authorisation Date: 11 July, 2016
Dosage: SOLUTION/DROPS
How can I launch a generic of XIIDRA before it's drug patent expiration?
More Information on Dosage
XIIDRA family patents